EQUTY INVESTMENT (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|---|
Dec. 18, 2018 |
Jun. 30, 2019 |
Jun. 30, 2018 |
Jun. 30, 2019 |
Jun. 30, 2018 |
May 06, 2019 |
|
| SHARE OF NET LOSSES OF EQUITY METHOD INVESTEE | $ (53,000) | $ (149,000) | ||||
| Goodwill | 3,392,000 | 3,392,000 | ||||
| ILiAD [Member] | ||||||
| Advisory and legal expenses | 41,000 | |||||
| ILiAD [Member] | Maximum [Member] | ||||||
| Investment | $ 5,000,000 | |||||
| ILiAD [Member] | Tranche One [Member] | ||||||
| Initial investment | $ 2,500,000 | |||||
| Description for the terms of allowed-to-proceed notice under aggrement | On May 2, 2019, ILiAD notified the Company that it had received an "allowed to proceed" notice from the FDA permitting ILiAD to advance to the Phase 2b clinical study of its BP2E1 vaccine. ILiAD elected to permit its Class C investors (including the Company) to bifurcate their tranche 2 commitments such that 40% would be currently due and 60% (additional $1,500,000 investment by the Company) would be due when ILiAD receives satisfactory safety data from the clinical study. | |||||
| ILiAD [Member] | Tranche Two [Member] | ||||||
| Initial investment | $ 2,500,000 | $ 2,500,000 | ||||
| ILiAD [Member] | Class C units [Member] | ||||||
| Investment | $ 1,000,000 | |||||
| Units purchase | 377,358 | |||||
| Price per unit | $ 2.65 | |||||
| Warrants to purchase units | 124,528 | |||||
| Exercise price | $ 3.50 | |||||
| Ownership percentage | 8.40% | |||||
| ILiAD [Member] | Class C units [Member] | Maximum [Member] | ||||||
| Investment | $ 16,200,000 | |||||
| ILiAD [Member] | Class C units [Member] | Tranche One [Member] | ||||||
| Units purchase | 1,111,111 | 1,111,111 | ||||
| Price per unit | $ 2.25 | $ 2.25 | ||||
| ILiAD [Member] | Class C units [Member] | Tranche Two [Member] | ||||||
| Units purchase | 943,396 | |||||
| Price per unit | $ 2.65 | |||||
| Warrants to purchase units | 311,320 | |||||
| Exercise price | $ 3.50 | |||||